Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycerophosphodiester phosphodiesterase 1 (GDE1)
- Target
- GDE1
- Molecular classification
- Enzyme, Phosphodiesterase, Integral membrane protein
01
Overview
Glycerophosphodiester phosphodiesterase 1 (GDE1) is an approximately 43 kDa integral membrane glycoprotein characterized by a conserved GDE domain serving as its catalytic site. Localized mainly to internal cell membranes, GDE1 hydrolyzes glycerophosphodiesters such as glycerophosphoinositol and glycerophosphoserine, producing inositol and glycerol 3-phosphate. Its activity is regulated via G protein-coupled receptor (GPCR) signaling, interacting with regulator of G protein signaling (RGS) proteins, and is essential for membrane phospholipid metabolism, intracellular trafficking, and potentially neural signaling by recycling serine from glycerophosphoserine pools in the nervous system. Knockout models show dramatic alteration of related metabolites in the brain, suggesting critical roles in neurochemical homeostasis, but no direct disease associations, biomarkers for patient selection, or interacting drugs have been validated.
- Other names
- MIR16Glycerophosphoinositol glycerophosphodiesterase GDE1Lysophospholipase D GDE1Membrane-interacting protein of RGS16RGS16-interacting membrane protein363E6.2GDE1/MIR16
02
Mechanism of action
Enzyme inhibition or modulation (hypothetical for drugs: would inhibit or enhance GDE1's phosphodiesterase activity)
03
Biological functions
Hydrolysis of glycerophosphodiesters (e.g., glycerophosphoinositol, glycerophosphoserine, glycerophosphoglycerate)Regulation of membrane phospholipid compositionModulation of G protein-mediated signaling (via interaction with RGS proteins and GPCR-regulated enzyme activity)Serine recycling in nervous system (through hydrolysis of glycerophosphoserine)
04
Disease associations
Neurobiology/Neurodegeneration (altered brain metabolite profiles in GDE1 knockout mice, with potential relevance for neural signaling)Other (possible roles in G protein-regulated membrane trafficking and cell signaling)
05
Safety considerations
Unknown (no direct safety concerns reported, but modulation could impact neural signaling or membrane metabolism)
06
Interacting drugs
None known
07
Biomarkers
Glycerophosphoinositol (and its derivatives; elevated in tissues lacking GDE1)Glycerophosphoserine (potential marker, as its levels are altered in GDE1 knockout models)
Beyond the preview
Go deeper on Glycerophosphodiester phosphodiesterase 1 (GDE1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glycerophosphodiester phosphodiesterase 1 (GDE1).